Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Catal­ent re­port­ed a slight rev­enue up­swing dur­ing its lat­est quar­ter­ly re­sults, which CEO Alessan­dro Masel­li ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine ...

Sana Biotech­nol­o­gy is prun­ing its pipeline and head­count for the sec­ond time in around a year to stretch its cash and ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Health systems and hospitals across the US have been rolling out artificial intelligence tools to help doctors with administrative tasks like taking notes, coding visits, and responding ...